Covidien plc Form 425 July 09, 2014

Town Hall Meeting July 9, 2014 Omar Ishrak Chairman and CEO Medtronic, Inc.

Filed by Medtronic, Inc. (SEC File No.: 001-07707) pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934

Subject Company: Covidien plc SEC File No.: 001-33259

Date: July 9, 2014

Medtronic to Acquire Covidien Creates the premier global medical technology and services company with unmatched breadth and patient reach

Agenda About Medtronic Strategic Fit Integration Guidelines Combined Impact Q&A COVIDIEN

About Medtronic

Fulfilling Unmet Medical Needs

The Medtronic Mission: A Shared Sense of Purpose To contribute to human welfare alleviate pain, restore health, and extend life To direct our growth in the areas of maximum strength and ability To strive without reserve for the greatest reliability

and quality
to be recognized as a company of
dedication, honesty, integrity, and service
To make a fair profit
To recognize the personal worth of employees
To maintain good citizenship as a company.

Improve Clinical
Outcomes
Expand Access
Optimize Cost
and Efficiency
Universal Healthcare Needs

Economic Value Globalization Strategies Therapy Innovation Universal HC needs Improve clinical

outcomes
Expand access
Optimize cost
and efficiency
Strategies to Address Healthcare Needs

Three Business Groups Address Broad Spectrum of Diseases
The data in this chart has been intentionally rounded to the nearest whole percentage and therefore does not sum to 100%.
Cardiac Rhythm
Disease
Management

30%

Coronary

11%

Structural

Heart

7%

Endovascular Therapies

5%

Diabetes

9%

Surgical

Technologies

9%

Neuromodulation

11%

Spine

19%

Strategic Fit

Combination Results in Strategic Diversification Restorative Restorative Therapies Group Therapies Group Spine Spine

Neuromodulation Neuromodulation Surgical Surgical Technologies Technologies Cardiac and Cardiac and Vascular Group Vascular Group Cardiac Rhythm Cardiac Rhythm Structural Heart Structural Heart Coronary Vascular Coronary Vascular Endovascular Endovascular Diabetes Diabetes Group Group Surgical Surgical Solutions Solutions Respiratory & Respiratory & Patient Care Patient Care

Vascular Vascular Therapies Therapies

Therapy Innovation:
Delivering strong
launch cadence of meaningful therapies
and procedures
Globalization:
Addressing the inequities
in healthcare access globally

Economic Value:
Becoming a leader
in value-based healthcare by incorporating
EV into our DNA
&
Uniquely positioned to expand our industryleading franchises through our three
differentiated strategies:
A Strong Strategic Fit
COVIDIEN

Three Key Benefits for Medtronic and Covidien Therapy Innovation
Therapy
Innovation
1.
Strengthen and enhance Peripheral Vascular and Neuroscience portfolios

2.Leverage adjacencies in Medtronic SurgicalTechnologies and Covidien Surgical Solutions3. Accelerate market adoption of early stageCovidien therapies

Combined Company Immediately Accelerates Ability to Expand Global Access countries 150 + locations 300 + combined EM revenue \$3.7B

Covidien products such as surgical tools and capital equipment are adopted earlier in hospitals, becoming a base for Medtronic chronic disease therapies Combined R&D and manufacturing breadth globally enables broader government partnerships

Broader presence facilitates more rapid expansion

A Robust and Unmatched Integrated Health Solutions Partner Diagnostic, Surgical, and Critical Care Technologies Value primarily realized in hospital efficiency

Chronic Disease
Therapies
Value primarily realized in
post-acute setting
Economic Value
COVIDIEN

Integration Guidelines

Guiding Principles for Integration

Continue to act as independent companies until transaction close

Keep focus and protect current business momentum in our

respective companies

Plan for integration now to be ready for Day 1 post-close

Focus on creating lasting value beyond stated cost synergies

Frequent, open communication on key decisions

Integration Team Structure
Integration Leads
Medtronic
Covidien
Medtronic
Covidien
Geoff Martha

Strategy & Master Planning Medtronic Covidien BUs/Franchises Medtronic Covidien Finance Medtronic Covidien Baseline & Value Capture Medtronic Covidien Culture, Change Mgmt, Comms Medtronic Covidien **Talent Management Processes** Medtronic Covidien Regions Medtronic Covidien **Growth Acceleration** Medtronic Covidien **Human Resources** Medtronic Covidien IT Medtronic Covidien Mfg/Supply Chain Medtronic Covidien Legal/Gov t Affairs Medtronic Covidien Clinical/Regulatory Medtronic Covidien Quality Medtronic Covidien Cross-functional teams Commercial teams

Functional teams

Bill Burke

Medtronic Covidien

Steering Committee

Integration Management Office (IMO)

Strategy & Business Dev Medtronic Covidien

Combined Impact

Transforming Healthcare Around the World to Improve More Lives
Every
3
seconds

Together:

\$27 Billion Healthcare Leader

87,000+ Employees Life-Changing Impact for Millions of Patients

Q&A

NO OFFER OR SOLICITATION

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or businesses of the solicitation of any vote or approval in any jurisdiction pursuant to the acquisition, the merge sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be mad meeting the requirements of Section 10 of the Securities Act of 1933, as amended.


IMPORTANT ADDITIONAL INFORMATION WILL BE FILED WITH THE SEC

New Medtronic will file with the Securities and Exchange Commission (the SEC), a registration statement on Form S-4 tha

Medtronic and Covidien that also constitutes a Prospectus of New Medtronic. Medtronic and Covidien plan to mail to their restatement/Prospectus (including the Scheme) in connection with the transactions. INVESTORS AND SHAREHOLDERS AR STATEMENT/PROSPECTUS (INCLUDING THE SCHEME) AND OTHER RELEVANT DOCUMENTS FILED OR TO B AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MEDTRONIC, COVIDIEN, N MATTERS. Investors and security holders will be able to obtain free copies of the Joint Proxy Statement/Prospectus (including with the SEC by New Medtronic, Medtronic and Covidien through the website maintained by the SEC at www.sec.gov. In add able to obtain free copies of the Joint Proxy Statement/Prospectus (including the Scheme) and other documents filed by Medtro by contacting Medtronic Investor Relations at investor.relations@medtronic.com or by calling 763-505-2696, and will be able Statement/Prospectus (including the Scheme) and other documents filed by Covidien by contacting Covidien Investor Relation by calling 508-452-4650.

PARTICIPANTS IN THE SOLICITATION

Medtronic, New Medtronic and Covidien and certain of their respective directors and executive officers and employees may be solicitation of proxies from the respective shareholders of Medtronic and Covidien in respect of the transactions contemplated Statement/Prospectus. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the s shareholders of Medtronic and Covidien in connection with the proposed transactions, including a description of their direct or or otherwise, will be set forth in the Joint Proxy Statement/Prospectus when it is filed with the SEC. Information regarding Me is contained in Medtronic s Annual Report on Form 10-K for the fiscal year ended April 25, 2014 and its Proxy Statement on 2013, which are filed with the SEC. Information regarding Covidien s directors and executive officers is contained in Covidien fiscal year ended September 27, 2013 and its Proxy Statement on Schedule 14A, dated January 24, 2014, which are filed with the second contained in Covidien second contained in Covidien second contained in Covidien second contained in Covidien second contained contained in Covidien second contained contained in Covidien second contained contai



Cautionary Statement Regarding Forward-Looking Statements

Statements contained in this communication that refer to New Medtronic's and/or Covidien s estimated or anticipation and the statements contained in this communication that refer to New Medtronic's and/or Covidien s estimated or anticipation and the statements contained in this communication that refer to New Medtronic's and/or Covidien s estimated or anticipation and the statements contained in this communication that refer to New Medtronic's and/or Covidien s estimated or anticipation and the statements contained in this communication that refer to New Medtronic's and/or Covidien s estimated or anticipation and the statement of the statement including estimated synergies, or other non-historical facts are forward-looking statements that reflect Medtronic's and/or Covidperspective of existing trends and information as of the date of this communication. Forward looking statements generally will such as anticipate, believe, plan, could, should, estimate, expect, forecast, outlook, guidance, project, or other similar words, phrases or expressions. It is important to note that these possible, potential, predict, not predictions of actual performance. Actual results may differ materially from current expectations depending upon a number

Medtronic's business, Medtronic's business, Covidien s business and risks associated with the proposed transactions. These fa others, the inherent uncertainty associated with financial projections; restructuring in connection with, and successful close of, subsequent integration of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and benefits of the Covidien acquisition and the ability to recognize the anticipated synergies and acquisition acquisition acquisition and the ability acquisition that the required regulatory approvals for the proposed transactions are not obtained, are delayed or are subject to conditions the the anticipated size of the markets and continued demand for Medtronic's and Covidien's products; the impact of competitive p access to available financing (including financing for the acquisition or refinancing of Medtronic or Covidien debt) on a timely terms; the risks of fluctuations in foreign currency exchange rates; the risks and uncertainties normally incident to the medical competition in the medical device industry; product liability claims; the difficulty of predicting the timing or outcome of pendi government investigations; variability of trade buying patterns; the timing and success of product launches; the difficulty of pr outcome of product development efforts and regulatory agency approvals or actions, if any; potential for adverse pricing move defend or enforce intellectual property rights; difficulties or delays in manufacturing; reduction or interruption in supply; produ availability and pricing of third party sourced products and materials; risks associated with self-insurance and commercial insu compliance with governmental regulations applicable to New Medtronic's and Covidien's facilities, products and the laws and regulations, affecting among other things, pricing and reimbursement of pharmaceutical products; health care polassociated with international operations; changes in tax laws or interpretations that could increase New Medtronic's, Medtroni consolidated tax liabilities, including, if the transaction is consummated, changes in tax laws that would result in New Medtror domestic corporation for United States federal tax purposes; the loss of key senior management or scientific staff; and such other detailed in Medtronic's periodic public filings with the Securities and Exchange Commission, including but not limited to Med Form 10-K for the fiscal year ended April 25, 2014, in Covidien s periodic public filings with the Securities and Exchange Co limited to Covidien s Annual Report on Form 10-K for the fiscal year ended September 27, 2013, and from time to time in Mo other investor communications. Except as expressly required by law, each of New Medtronic and Medtronic disclaims any interor revise these forward-looking statements.

Statement Required by the Irish Takeover Rules

The directors of Medtronic accept responsibility for the information contained in this document. To the best of the knowledge of Medtronic (who have taken all reasonable care to ensure that such is the case), the information contained in this document is facts and does not omit anything likely to affect the import of such information.

Town Hall Meeting Omar Ishrak Chairman and CEO Medtronic, Inc.